Topical Treatment For Actinic Keratosis Therapeutics
1. Klisyri patent expiration
Treatment: Topical treatment of actinic keratosis of the face or scalp
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851470 | ALMIRALL | Composition and methods for modulating a kinase cascade |
Feb, 2029
(3 years from now) | |
| US8236799 | ALMIRALL | Biaryl compositions and methods for modulating a kinase cascade |
Dec, 2025
(11 days ago) | |
| US8980890 | ALMIRALL | Compositions and methods of treating cell proliferation disorders |
Dec, 2025
(11 days ago) | |
| US7300931 | ALMIRALL | Compositions for treating cell proliferation disorders |
Dec, 2030
(4 years from now) | |
| US10669236 | ALMIRALL | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide |
Sep, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617693 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(12 years from now) | |
| US11497750 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(12 years from now) | |
| US10323001 | ALMIRALL | Compositions for modulating a kinase cascade and methods of use thereof |
Dec, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
| New Dosing Schedule(D-192) | Jun 07, 2027 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Dosage: OINTMENT
More Information on Dosage
KLISYRI family patents
